Semazic is not recommended for use in patients with end-stage renal disease
middle (M) actuations at approximately the midpoint of the labeled number of doses
While the new indication for the drug means the TGA has satisfactory evidence of its benefits in regard to those particular conditions, it did not alter the cost of the drug
Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, Heuvel van den LP, et al: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase
When you first start the medication, your body is suddenly signaled to slow gastric emptyingthe rate at which your stomach releases food into the small intestine
Side effects are similar, but Tirzepatide may have a stronger impact on the digestive system